1. Home
  2. TYRA vs SDHC Comparison

TYRA vs SDHC Comparison

Compare TYRA & SDHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TYRA
  • SDHC
  • Stock Information
  • Founded
  • TYRA 2018
  • SDHC 2008
  • Country
  • TYRA United States
  • SDHC United States
  • Employees
  • TYRA N/A
  • SDHC N/A
  • Industry
  • TYRA Biotechnology: Pharmaceutical Preparations
  • SDHC
  • Sector
  • TYRA Health Care
  • SDHC
  • Exchange
  • TYRA Nasdaq
  • SDHC Nasdaq
  • Market Cap
  • TYRA 844.2M
  • SDHC 794.4M
  • IPO Year
  • TYRA 2021
  • SDHC 2024
  • Fundamental
  • Price
  • TYRA $14.86
  • SDHC $17.61
  • Analyst Decision
  • TYRA Strong Buy
  • SDHC Hold
  • Analyst Count
  • TYRA 5
  • SDHC 4
  • Target Price
  • TYRA $31.20
  • SDHC $17.38
  • AVG Volume (30 Days)
  • TYRA 238.5K
  • SDHC 103.1K
  • Earning Date
  • TYRA 11-14-2025
  • SDHC 11-05-2025
  • Dividend Yield
  • TYRA N/A
  • SDHC N/A
  • EPS Growth
  • TYRA N/A
  • SDHC N/A
  • EPS
  • TYRA N/A
  • SDHC N/A
  • Revenue
  • TYRA N/A
  • SDHC $1,013,967,000.00
  • Revenue This Year
  • TYRA N/A
  • SDHC $1.27
  • Revenue Next Year
  • TYRA N/A
  • SDHC $8.41
  • P/E Ratio
  • TYRA N/A
  • SDHC N/A
  • Revenue Growth
  • TYRA N/A
  • SDHC 22.89
  • 52 Week Low
  • TYRA $6.42
  • SDHC $15.00
  • 52 Week High
  • TYRA $17.78
  • SDHC $37.90
  • Technical
  • Relative Strength Index (RSI)
  • TYRA 56.47
  • SDHC 50.00
  • Support Level
  • TYRA $13.75
  • SDHC $17.21
  • Resistance Level
  • TYRA $16.05
  • SDHC $17.96
  • Average True Range (ATR)
  • TYRA 0.82
  • SDHC 0.71
  • MACD
  • TYRA 0.01
  • SDHC 0.16
  • Stochastic Oscillator
  • TYRA 54.35
  • SDHC 63.13

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

About SDHC Smith Douglas Homes Corp.

Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.

Share on Social Networks: